ArticlePLoS pathogens2015
Variable processing and cross-presentation of HIV by dendritic cells and macrophages shapes CTL immunodominance and immune escape.
Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- The Activation State of CD4 T Cells Alters Cellular Peptidase Activities, HIV Antigen Processing, and MHC Class I Presentation in a Sequence-Dependent Manner.Journal of immunology (Baltimore, Md. : 1950) · 2019Trial
- Mitogen-Activated Protein Kinases: Therapeutic Signaling Catalysts in Viral Immune Evasion.Pathogens (Basel, Switzerland) · 2026Review
- Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression.Journal for immunotherapy of cancer · 2024Article
- Intratumoral delivery of TransConCancer cell international · 2022Article
- A natural polymorphism of Mycobacterium tuberculosis in the esxH gene disrupts immunodomination by the TB10.4-specific CD8 T cell response.PLoS pathogens · 2020Article
- Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells.PLoS pathogens · 2020Article
- Current Challenges in Vaccinology.Frontiers in immunology · 2020Review
- Antigen Cross-Presentation by Macrophages.Frontiers in immunology · 2020Review
- The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.Journal of immunology research · 2020Review
- Unexpected Role of CD8 T Cells in Accelerated Clearance of Salmonella enterica Serovar Typhimurium from H-2 Congenic mice.Infection and immunity · 2019Article
- Antigen processing and presentation in HIV infection.Molecular immunology · 2019Review
- Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.Journal of virology · 2019Article
- Role of Dendritic Cells in Natural Immune Control of HIV-1 Infection.Frontiers in immunology · 2019Review
- Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability.Cancer immunology research · 2018Article
- Human in vivo-generated monocyte-derived dendritic cells and macrophages cross-present antigens through a vacuolar pathway.Nature communications · 2018Article
- Cross-priming induces immunodomination in the presence of viral MHC class I inhibition.PLoS pathogens · 2018Article
- Dendritic Cell Immune Responses in HIV-1 Controllers.Current HIV/AIDS reports · 2017Review
- Pulmonary Dendritic Cell Subsets Shape the Respiratory Syncytial Virus-Specific CD8+ T Cell Immunodominance Hierarchy in Neonates.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- The Role of Multiscale Protein Dynamics in Antigen Presentation and T Lymphocyte Recognition.Frontiers in immunology · 2017Article
- Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses.Journal of virology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Dendritic cells (DCs) and macrophages (Møs) internalize and process exogenous HIV-derived antigens for cross-presentation by MHC-I to cytotoxic CD8⁺ T cells (CTL). However, how degradation patterns of HIV antigens in the cross-presentation pathways affect immunodominance and immune escape is poorly defined. Here, we studied the processing and cross-presentation of dominant and subdominant HIV-1 Gag-derived epitopes and HLA-restricted mutants by monocyte-derived DCs and Møs. The cross-presentation of HIV proteins by both DCs and Møs led to higher CTL responses specific for immunodominant epitopes. The low CTL responses to subdominant epitopes were increased by pretreatment of target cells with peptidase inhibitors, suggestive of higher intracellular degradation of the corresponding peptides. Using DC and Mø cell extracts as a source of cytosolic, endosomal or lysosomal proteases to degrade long HIV peptides, we identified by mass spectrometry cell-specific and compartment-specific degradation patterns, which favored the production of peptides containing immunodominant epitopes in all compartments. The intracellular stability of optimal HIV-1 epitopes prior to loading onto MHC was highly variable and sequence-dependent in all compartments, and followed CTL hierarchy with immunodominant epitopes presenting higher stability rates. Common HLA-associated mutations in a dominant epitope appearing during acute HIV infection modified the degradation patterns of long HIV peptides, reduced intracellular stability and epitope production in cross-presentation-competent cell compartments, showing that impaired epitope production in the cross-presentation pathway contributes to immune escape. These findings highlight the contribution of degradation patterns in the cross-presentation pathway to HIV immunodominance and provide the first demonstration of immune escape affecting epitope cross-presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.